中文摘要：

目的：探讨脑膜瘤组织病理表型与其WHO分级及预后的相关性。方法：采用免疫组化检测120例脑膜瘤病理标本中Vimentin、EMA、S-100、GFAP、Ki67、P53的表达,分析以上分子与脑膜瘤WHO分级、术后复发的相关性。结果：（1）120例脑膜瘤中Vimentin均为阳性表达,EMA平均表达阳性率为90%,Vimentin和EMA表达在3组WHO分级脑膜瘤的组织中差异无统计学意义。（2）S-100平均表达阳性率为23%,在3组WHO分级的脑膜瘤中差异无统计学意义;GFAP平均表达阳性率为4%,在WHOⅡ级脑膜瘤中表达明显高于WHOⅠ级与WHOⅢ级。（3）Ki67和P53的平均阳性表达率为46%和32%,两者均随着脑膜瘤WHO级别升高而表达增高。（4）Ki67的表达与脑膜瘤的复发有相关性。结论：Vimentin和EMA的组织表达阳性可作为脑膜瘤的分子诊断特征;Ki67和P53与脑膜瘤恶性程度密切相关,可以作为良恶性鉴别的分子标志物;Ki67可作为脑膜瘤复发的预后指标之一。

英文摘要：

Objective： To investigate the correlation of pathological phenotype and prognosis of meningioma with the WHO classification. Methods： The expressions of Vimentin,EMA,S-100,GFAP,Ki67 and P53 in 120 cases of meningioma pathological specimens were detected using immunohistochemical method, and the relevance between these molecular markers and WHO classification in meningioma and also its prognosis was analyzed.Results：（ 1） Of 120 cases of meningioma,Vimentin expression was all positive. EMA expression positive rate was 90%on average. There was no obvious difference between Vimentin and EMA expression among the three meningioma tissues of the WHO classification.（ 2） The average expression rate of S-100 was 23% and there was not obvious difference among the three groups. The average expression rate of GFAP was 4% and it was significantly higher expressed in WHO Ⅱ meningioma tissues than in WHO Ⅰand WHO Ⅲ meningioma tissues.（ 3） The average expression rate of Ki67 and P53 were 46% and 32%,both increasing along with the WHO degree.（ 4） The expression of Ki67 was associated with the recurrence of meningioma. Conclusion： The expression of Vimentin and EMA can be used as molecular markers of meningioma. The expression of Ki67 and P53 are closely related to WHO degree of meningioma and can be used as molecular markers identifying benign or malignancy meningioma. Ki67 can be used as a prognostic indicator for recurrent meningioma.